Cargando…

Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer

Prostate-specific antigen (PSA) is regarded as the most sensitive biomarker for prostate cancer. Although androgen/androgen receptor (AR) signaling promotes prostate cancer progression, suppression of AR signaling induces chemokine (CC motif) ligand 2 (CCL2), which enables prostate cancer cells to g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Izumi, Kouji, Mizokami, Atsushi, Lin, Hsiu-Ping, Ho, Hui-Min, Iwamoto, Hiroaki, Maolake, Aerken, Natsagdorj, Ariunbold, Kitagawa, Yasuhide, Kadono, Yoshifumi, Miyamoto, Hiroshi, Huang, Chiung-Kuei, Namiki, Mikio, Lin, Wen-Jye
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Clinical Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4885000/ https://www.ncbi.nlm.nih.gov/pubmed/26701731 http://dx.doi.org/10.18632/oncotarget.6690

Ejemplares similares

CCL2 induces resistance to the antiproliferative effect of cabazitaxel in prostate cancer cells
por: Natsagdorj, Ariunbold, et al.
Publicado: (2018)

Tumor-associated macrophages promote prostate cancer migration through activation of the CCL22–CCR4 axis
por: Maolake, Aerken, et al.
Publicado: (2016)

C‐C motif ligand 5 promotes migration of prostate cancer cells in the prostate cancer bone metastasis microenvironment
por: Urata, Satoko, et al.
Publicado: (2018)

Tumor necrosis factor‐α induces prostate cancer cell migration in lymphatic metastasis through CCR7 upregulation
por: Maolake, Aerken, et al.
Publicado: (2018)

Predictive factor and antihypertensive usage of tyrosine kinase inhibitor-induced hypertension in kidney cancer patients
por: IZUMI, KOUJI, et al.
Publicado: (2014)

Establishment and characterization of two cabazitaxel-resistant prostate cancer cell lines
por: Machioka, Kazuaki, et al.
Publicado: (2018)

Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice
por: Mizokami, Atsushi, et al.
Publicado: (2017)

Decreasing trend in prostate cancer with high serum prostate-specific antigen levels detected at first prostate-specific antigen-based population screening in Japan
por: Kitagawa, Yasuhide, et al.
Publicado: (2014)

Prognosis of patients with prostate cancer and middle range prostate - specific antigen levels of 20 – 100 ng / mL
por: Iwamoto, Hiroaki, et al.
Publicado: (2019)

Is the C-C Motif Ligand 2–C-C Chemokine Receptor 2 Axis a Promising Target for Cancer Therapy and Diagnosis?
por: Iwamoto, Hiroaki, et al.
Publicado: (2020)

Trends of clinical symptoms and prognosis of middle-aged prostate cancer patients after instigation of prostate specific antigen-based population screening
por: Kitagawa, Yasuhide, et al.
Publicado: (2013)

Risk Factors Affecting Decreased Libido Among Middle-Aged to Elderly Men; Nocturnal Voiding is an Independent Risk Factor of Decreased Libido
por: Shigehara, Kazuyoshi, et al.
Publicado: (2021)

An Unusual Prostate-Specific Antigen Decrease in an Advanced Castration-Resistant Prostate Cancer Patient with Intracerebral Hemorrhage Subsequently Treated with Luteinizing Hormone-Releasing Hormone Antagonist
por: Izumi, Kouji, et al.
Publicado: (2013)

Comparison of the Prognostic Value of Inflammatory and Nutritional Indices in Nonmetastatic Renal Cell Carcinoma
por: Makino, Tomoyuki, et al.
Publicado: (2023)

Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation
por: Izumi, Kouji, et al.
Publicado: (2013)

Inflammatory Myofibroblastic Tumor of the Urinary Bladder with Benign Pelvic Lymph Node Enlargement: A Case Report
por: Machioka, Kazuaki, et al.
Publicado: (2014)

Testosterone and Bone Health in Men: A Narrative Review
por: Shigehara, Kazuyoshi, et al.
Publicado: (2021)

Testosterone Replacement Therapy for Patients with Hypogonadism after High Dose-Rate Brachytherapy for High-Risk Prostate Cancer: A Report of Six Cases and Literature Review
por: Kadomoto, Suguru, et al.
Publicado: (2020)

Impact of Pelvic Anatomical Changes Caused by Radical Prostatectomy
por: Kadono, Yoshifumi, et al.
Publicado: (2022)

Long-term survival following multidisciplinary treatment of metastatic sarcomatoid renal cell carcinoma: a case report
por: Yaegashi, Hiroshi, et al.
Publicado: (2015)

Suppressive Role of Androgen/Androgen Receptor Signaling via Chemokines on Prostate Cancer Cells
por: Izumi, Kouji, et al.
Publicado: (2019)

Prostate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in Asia
por: Kitagawa, Yasuhide, et al.
Publicado: (2015)

A novel screening strategy for clinically significant prostate cancer in elderly men over 75 years of age
por: Iwamoto, Hiroaki, et al.
Publicado: (2020)

Long response duration to pembrolizumab in metastatic, castration-resistant prostate cancer with microsatellite instability-high and neuroendocrine differentiation: A case report
por: Yoshida, Tsukasa, et al.
Publicado: (2022)

A case of adrenal lymphangioma resected laparoscopically with minimal invasiveness
por: Yaegashi, Hiroshi, et al.
Publicado: (2020)

Prospective longitudinal comparative study of health-related quality of life and treatment satisfaction in patients treated with hormone therapy, radical retropubic prostatectomy, and high or low dose rate brachytherapy for prostate cancer
por: Miwa, Sotaro, et al.
Publicado: (2013)

Background factors and short-term health-related quality of life in patients who initially underwent radical prostatectomy or androgen deprivation therapy for localized prostate cancer in a Japanese prospective observational study (J-CaP Innovative Study-1)
por: Ueno, Satoru, et al.
Publicado: (2018)

Optimal treatment for castration-resistant prostate cancer
por: Izumi, Kouji, et al.
Publicado: (2014)

Metastatic Urothelial Carcinoma of the Prepuce and Glans Penis: Suspected Implantation of Non-Muscle-Invasive Bladder Cancer via Urine
por: Makino, Tomoyuki, et al.
Publicado: (2014)

Role of hormonal therapy for prostate cancer: perspective from Japanese experiences
por: Namiki, Mikio, et al.
Publicado: (2012)

Efficacy and safety of keishibukuryogan, a traditional Japanese Kampo medicine, for hot flashes in prostate cancer patients receiving androgen deprivation therapy
por: Shigehara, Kazuyoshi, et al.
Publicado: (2020)

Efficacy of keishibukuryogan for hot flashes in prostate cancer patients receiving androgen deprivation therapy: a sub-analysis focusing on hormonal and cytokine levels
por: Shigehara, Kazuyoshi, et al.
Publicado: (2023)

Relation between athletic club affiliation from school age and future serum free testosterone levels in Japan: A cross‐sectional study
por: Kato, Yuki, et al.
Publicado: (2023)

Androgen replacement therapy for cancer‐related symptoms in male: result of prospective randomized trial (ARTFORM study)
por: Izumi, Kouji, et al.
Publicado: (2021)

Investigating the mechanism underlying urinary continence using dynamic MRI after Retzius-sparing robot-assisted radical prostatectomy
por: Kadono, Yoshifumi, et al.
Publicado: (2022)

Carbon dioxide gas embolism during robot‐assisted laparoscopic partial nephrectomy
por: Nakagawa, Ryunosuke, et al.
Publicado: (2022)

Decreased febrile neutropenia during inpatient chemotherapy for urologic cancer during coronavirus disease 2019 pandemic
por: Toriumi, Ren, et al.
Publicado: (2022)

Comparison of Clinical Outcomes between Robot-Assisted Partial Nephrectomy and Cryoablation in Elderly Patients with Renal Cancer
por: Kawaguchi, Shohei, et al.
Publicado: (2022)

Ischemic proctitis after low‐dose‐rate brachytherapy using hydrogel spacer for prostate cancer
por: Toriumi, Ren, et al.
Publicado: (2022)

Testosterone Deficiency and Nocturia: A Review
por: Shigehara, Kazuyoshi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rfjidf4gvthigoimsa65od8j3r